Prescribing guide
Hemlibra (emicizumab-kxwh)Loading and maintenance dosing, aPCC boxed warning, coagulation assay interference and prior authorization criteriaFor prescribers and their offices treating hemophilia A: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; specialty pharmacy, treatment center or hospital pharmacy dispensing after prior authorization; HEMLIBRA Access Solutions starts only once both the Prescriber Service Form and the Patient Consent Form are received.
Example PA threshold
Cigna example: documented hemophilia A with or without inhibitors, routine prophylaxis, hemophilia specialist, prophylactic bypassing agents stopped or prophylactic FVIII stopped within 4 weeks, no ITI with inhibitors, no concurrent Alhemo, Hympavzi or Qfitlia.
Monitoring
No scheduled lab monitoring in the label; do not use aPTT-based assays to monitor Hemlibra, dose factor or measure inhibitors; watch for TMA and thrombosis if aPCC is given and for loss of efficacy from neutralizing antibodies.
Support line
HEMLIBRA Access Solutions, 877-233-3981, Case Managers and Field Reimbursement Managers for benefits checks, PA and appeal resources; copay as little as $0 with up to $15,000 a year for commercial plans at (844) 436-2672; Genentech Patient Foundation at (888) 941-3331.
Give your patient their plan
A one-page handout for starting Hemlibra, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/hemlibraBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in HEMLIBRA Access Solutions | Submit the Prescriber Service Form by download, Quick Enroll or My Patient Solutions, and have the patient complete the Patient Consent Form. Both must be received before Genentech can begin; providing unrequested documents delays processing. | HEMLIBRA Access Solutions |
| Benefits investigation | Access Solutions can confirm coverage, whether PA is required, and which specialty pharmacy the plan prefers. More than 100 specialty pharmacies are in network; Genentech does not steer to any one. | HEMLIBRA Access Solutions |
| Plan the transition | Stop prophylactic bypassing agents the day before the first dose; prophylactic FVIII may continue during week 1. Discuss dosing of on-demand bypassing agents or FVIII with the patient or caregiver before starting. | FDA label |
| Train the injector | Instruct the patient or caregiver in subcutaneous technique and assess ability and suitability for home use. Self-administration is not recommended under age 7; upper outer arm injections by a caregiver or healthcare provider only. | FDA label |
| Order supplies | Each dose needs a syringe (1 mL for up to 1 mL; 2 or 3 mL for more than 1 mL up to 2 mL), an 18 gauge transfer needle with a 5-micron filter, and a 25 to 27 gauge injection needle. Do not combine 30mg/mL and 150mg/mL vials in one injection. | FDA label |
| Counsel on labs | Tell the patient or caregiver that Hemlibra can cause false clotting test results, and to tell any healthcare provider before blood tests or procedures. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, September 1, 2026. Approval a year at a time; renewal asks for a beneficial response, such as fewer or less severe bleeds. This policy took effect on September 1, 2026 and cites the July 2025 Hemlibra label, which is still current. Its September 2026 update dropped an earlier requirement for an inhibitor test within the past 30 days. Treating a breakthrough bleed with factor VIII or a bypassing agent is allowed under it. For people without inhibitors, its text still lists no past factor VIII use as a condition. Its change log describes removing a related rule, so the office may need to confirm this with Cigna. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Indication | Routine prophylaxis to prevent or reduce the frequency of bleeding episodes | Treatment plan in the note | Cigna policy |
| Diagnosis | Hemophilia A with factor VIII inhibitors, or hemophilia A without factor VIII inhibitors | Chart documentation of the diagnosis [documentation required] | Cigna policy |
| Prior FVIII, without inhibitors | The initial-therapy text for patients without inhibitors includes the line 'Patient has not received Factor VIII therapy in the past', although the change log describes removing a related requirement | Confirm with Cigna whether this line applies before submitting for a patient switching from FVIII | Cigna policy |
| Bypassing agents, with inhibitors | According to the prescriber, prophylactic bypassing agents will be discontinued; on-demand use for breakthrough bleeds is permitted | Agent, dose and stop date | Cigna policy |
| Factor VIII, without inhibitors | According to the prescriber, prophylactic FVIII will stop no later than 4 weeks after the first Hemlibra dose; on-demand FVIII is permitted | Product, dose and planned stop date | Cigna policy |
| Immune tolerance induction | With inhibitors, the patient is not undergoing ITI | Statement in the note | Cigna policy |
| Prescriber | Prescribed by or in consultation with a hemophilia specialist | Specialty on the request, or HTC consult note | Cigna policy |
| Dosing | 3mg/kg weekly for 4 weeks, then 1.5mg/kg weekly, 3mg/kg every 2 weeks or 6mg/kg every 4 weeks | Current weight and the chosen regimen | Cigna policy |
| Renewal | Beneficial response, such as fewer bleeds, less severe bleeds, fewer treated bleeds or fewer spontaneous bleeds | Bleed log or ABR comparison | Cigna policy |
Hemlibra dosing and titration
| When | Label | Source |
|---|---|---|
| Weeks 1 to 4 | Loading dose 3mg/kg subcutaneously once weekly. Mean trough at week 5 was 52.6 ± 13.6 µg/mL. | FDA label |
| Week 5 onward | 1.5mg/kg once weekly, 3mg/kg once every 2 weeks, or 6mg/kg once every 4 weeks. Steady-state troughs 51.2, 46.9 and 38.5 µg/mL respectively. | FDA label |
| Missed dose | Give as soon as possible, then resume the usual schedule. Do not give 2 doses on the same day. | FDA label |
| Vials | Single-dose vials, 1 per carton: 12mg/0.4 mL (grey), 30mg/mL (sky blue), 60mg/0.4 mL (purple), 105mg/0.7 mL (turquoise), 150mg/mL (brown), 300mg/2 mL (yellow). | FDA label |
| Infants under 6 months | Predicted concentrations 19% to 33% lower than in older patients, especially on the every-2-week and every-4-week regimens. | FDA label |
| Renal and hepatic impairment | No PK effect of mild or moderate renal or hepatic impairment; not studied in severe impairment. | FDA label |
| Storage | 2°C to 8°C in the carton, not frozen or shaken; unopened vials may total 7 days out of the fridge below 30°C; use immediately once drawn up. | FDA label |
Monitoring the Hemlibra label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| If aPCC is given | Signs of TMA: thrombocytopenia, microangiopathic hemolytic anemia, acute kidney injury | TMA in 3 of 37 patients who received aPCC; discontinue aPCC and interrupt Hemlibra if TMA occurs; improvement seen within 1 week | FDA label |
| If aPCC is given | Clinical, imaging or lab signs of thromboembolism | Thrombotic events in 2 of 37 aPCC-exposed patients; none needed anticoagulation; discontinue aPCC and interrupt Hemlibra; improvement within 1 month | FDA label |
| Any time | Coagulation labs | Do not use intrinsic pathway clotting-based tests to monitor Hemlibra, dose factor replacement or anticoagulation, or measure FVIII inhibitor titers; use bovine chromogenic FVIII or chromogenic Bethesda assays. Effects can persist up to 6 months after the last dose. | FDA label |
| Any time | Breakthrough bleeding | Anti-emicizumab antibodies in 5.1% (34/668); loss of efficacy from neutralizing antibodies under 1%. Assess promptly and consider a change in treatment. | FDA label |
| Any time | Injection site reactions, headache, arthralgia | 22%, 15% and 15% in pooled trials (N = 391); 93% of ISRs resolved without treatment | FDA label |
| Renewal | Bleed response | Cigna approves 1 year at a time; continuation requires a beneficial response according to the prescriber | Cigna policy |
Hemlibra drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| aPCC (FEIBA) | Hypercoagulability; TMA and thrombotic events with a cumulative average >100 U/kg/24 hours for 24 hours or more. 13 of 130 aPCC treatment instances met that threshold; all 5 events occurred among them. | FDA label |
| Prophylactic bypassing agents | Discontinue the day before starting Hemlibra | FDA label |
| Prophylactic FVIII | May continue during the first week of Hemlibra | FDA label |
| Coagulation assays | Overly shortened aPTT and false one-stage FVIII results; false-negative clotting-based Bethesda; human-protein chromogenic FVIII assays may overestimate hemostatic potential | FDA label |
| Other drugs | No drug-drug interaction studies have been conducted | FDA label |
| Pregnancy and contraception | No human or animal reproduction data; use in pregnancy only if benefit outweighs risk; women of childbearing potential should use contraception | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below wants a documented hemophilia A diagnosis, routine prophylaxis use and a hemophilia specialist. A Field Reimbursement Manager or Case Manager can share appeal resources, but HEMLIBRA Access Solutions cannot complete or submit an appeal.
- The plan wants prophylaxis agents stoppedCigna asks the hematologist to confirm that prophylactic bypassing agents will stop. For people without inhibitors, prophylactic factor VIII must stop within 4 weeks of the first dose. Agents used to treat a breakthrough bleed are still allowed.
- You are on immune tolerance inductionFor people with inhibitors, Cigna's policy covers Hemlibra only for patients who are not undergoing immune tolerance induction. The hematologist decides the order of treatments.
- You also take another non-factor drugCigna does not cover Hemlibra used together with Alhemo, Hympavzi or Qfitlia. The request needs to show a single non-factor prophylaxis drug.
- The prescription went to the wrong pharmacyHemlibra is dispensed through specialty, treatment center and hospital pharmacies. A Case Manager can tell the office which specialty pharmacy your plan requires, and the office resends it there.
- A copay you cannot payWith commercial insurance, the copay program may bring the cost to as little as $0, with up to $15,000 a year in help. Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA and DoD plans are excluded. Independent foundations may help people with commercial or public insurance, including Medicare and Medicaid.
- No insurance, or no coverage for HemlibraThe Genentech Patient Foundation gives Hemlibra free to people who qualify. Uninsured patients, or insured patients without Hemlibra coverage, need incomes under $150,000.
HEMLIBRA Access Solutions
- A Case Manager who explains your coverage, finds financial help, and works with the doctor's office and specialty pharmacy
- A benefits check showing whether Hemlibra is covered, whether prior authorization is needed and which specialty pharmacy the plan prefers
- A copay program for commercial insurance, as little as $0 per treatment, up to $15,000 a year, at (844) 436-2672
- No copay help for Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA or DoD coverage
- Referrals to independent copay foundations, including for people on Medicare or Medicaid
- Free Hemlibra from the Genentech Patient Foundation for people who qualify, at (888) 941-3331
- A sharps disposal program through 1-866-HEMLIBRA (1-866-436-5427) Supplies and storage
Questions prescribers' offices ask about Hemlibra
What is the Hemlibra dose?
3mg/kg subcutaneously once weekly for 4 weeks, then 1.5mg/kg weekly, 3mg/kg every 2 weeks or 6mg/kg every 4 weeks, per the July 2025 label. The label says the maintenance choice rests on provider preference, considering regimens that may improve adherence.
What does the Hemlibra boxed warning say about aPCC?
TMA and thrombotic events were reported when aPCC averaged a cumulative >100 U/kg/24 hours for 24 hours or more, per the July 2025 label. Monitor for both if aPCC is given, and discontinue aPCC and suspend Hemlibra if symptoms occur. The interaction may persist up to 6 months after the last dose.
Which coagulation tests does Hemlibra affect?
Per the July 2025 label, Hemlibra affects ACT, aPTT and all aPTT-based assays for up to 6 months after the last dose, including one-stage FVIII activity, aPTT-based APC-R and clotting-based Bethesda titers. PT-based and chromogenic single-factor assays other than FVIII, immuno-based assays and genetic tests are unaffected; bovine chromogenic FVIII assays can measure FVIII and inhibitor titers.
How are bypassing agents and factor VIII handled when starting Hemlibra?
Per the July 2025 label, prophylactic bypassing agents stop 1 day before the first dose, and prophylactic FVIII may continue through week 1. The label asks prescribers to discuss dosing of on-demand bypassing agents or FVIII with the patient before starting.
What do insurers ask for to approve Hemlibra?
Cigna's policy, effective September 1, 2026 and citing the July 2025 label, asks for a documented diagnosis of hemophilia A with or without inhibitors and routine prophylaxis use. It also wants a hemophilia specialist, labeled dosing, and stopping prophylactic bypassing agents, or FVIII within 4 weeks. Inhibitor patients must not be on immune tolerance induction.
Free email alert
Get an email when the Hemlibra label changes
One email the day the FDA revises the Hemlibra prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Hemlibra only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - HEMLIBRA- emicizumab injection, solution (prescribing information and Medication Guide, revised July 2025, SPL version 17), Genentech, via DailyMed, 2025-07-11.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-07.
- HEMLIBRA® (emicizumab-kxwh) Dosing Options, Genentech, 2026-11-07.
- HEMLIBRA® (emicizumab-kxwh) Supplies and Storage, Genentech, 2026-11-07.
- Financial Assistance Options | HEMLIBRA® (emicizumab-kxwh), Genentech, 2026-11-07.
- Case Managers | HEMLIBRA® (emicizumab-kxwh), Genentech, 2026-11-07.
- Genentech Pro | HEMLIBRA® (emicizumab-kxwh), Genentech, 2026-11-07.
- Hemophilia – Non-Factor Routine Prophylaxis Products – Hemlibra, Drug Coverage Policy IP0121, Cigna, 2026-09-01.
- BLA 761083/S-020 supplement approval letter, hypersensitivity in postmarketing experience, FDA, 2025-07-08.
- BLA 761083/S-018 supplement approval letter, 12 mg/0.4 mL vial and immunogenicity updates, FDA, 2024-01-31.
- BLA 761083/S-015 supplement approval letter, rash, urticaria and angioedema in postmarketing experience, FDA, 2022-06-06.
- BLA 761083/S-013 supplement approval letter, updated immunogenicity data, FDA, 2021-12-16.
- BLA 761083/S-011 supplement approval letter, hepatic and renal impairment and aPCC interaction up to 6 months, FDA, 2021-09-02.
- BLA 761083/S-002 and S-004 supplement approval letter, hemophilia A with or without inhibitors and 6 mg/kg every 4 weeks, FDA, 2018-10-04.
- BLA 761083 approval letter, HEMLIBRA (emicizumab-kxwh) injection, FDA, 2017-11-16.
A reference drawn from the July 11, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.